Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

SENS - Senseonics Holdings, Inc. Последние... | Finranks

Home

SENS

S

Senseonics Holdings, Inc. (SENS)

NMS – Цена в реальном времени. Валюта: USD

6.56

0.00 (0.00%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

6.50

-0.06 (-0.91%)

После закрытия: Mar 27, 2026, 7:44 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Senseonics Reports Strong One-Year Real-World Data for Eversense 365

Senseonics Reports Strong One-Year Real-World Data for Eversense 365

SENS highlights strong one-year real-world data for Eversense 365, reinforcing adherence, glucose control and long-term adoption potential.

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes

Wall Street Analysts Predict a 124.49% Upside in Senseonics (SENS): Here's What You Should Know

Wall Street Analysts Predict a 124.49% Upside in Senseonics (SENS): Here's What You Should Know

The consensus price target hints at a 124.5% upside potential for Senseonics (SENS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript

Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript

Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) Reports Q4 Loss, Tops Revenue Estimates

Senseonics Holdings (SENS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.

SENS Eversense 365 Integrated With twiist Gains Full Availability

SENS Eversense 365 Integrated With twiist Gains Full Availability

Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.

Видео

No Data

There is no data to display

Пресс-релизы

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes